Pharmerging Market – Biosimilars Capturing Tender-Driven Market Share

Market Overview

The pharmerging market is witnessing rapid biosimilar adoption as payers in emerging economies leverage tender-based procurement to capture originator market share at scale. Unlike mature markets where prescriber loyalty slows switching, pharmerging payers can switch entire patient populations in a single tender cycle. The Pharmerging Market is projected to grow through 2035, with biosimilars representing the fastest-growing product segment at an 11.61% CAGR. More than USD 60 billion of biologic originator revenue faces loss of exclusivity globally through 2030.

Pharmerging economies are uniquely positioned to capture biosimilar savings because they lack entrenched prescriber preferences and operate centralized procurement systems. The growth of the pharmerging market reflects this dynamic, as governments prioritize cost-effective biologics to expand treatment access. China, India, and Russia are leading biosimilar adoption, with domestic manufacturers capturing significant tender volume.

Current Market Landscape

Domestic biosimilar manufacturers competing on tender price. Government reimbursement lists including biosimilar alternatives. Oncology biosimilars driving significant savings in cancer care. Insulin biosimilars expanding diabetes treatment access. Monoclonal antibody biosimilars entering immunology and oncology. Tender-driven biosimilar ecosystem.

Emerging Trends

Interchangeability designations enabling pharmacy-level substitution. Real-world evidence demonstrating biosimilar safety and efficacy. Export-oriented biosimilar manufacturing in India and South Korea. Partnerships between originators and biosimilar developers. Expansion into complex biologics beyond monoclonal antibodies. Biosimilar acceleration.

Future Outlook

Biosimilars will likely capture majority share in tender-driven markets. Domestic manufacturers will likely expand export presence. Complex biosimilars will likely face increasing competition. Regulatory convergence will likely facilitate international trade. Market transformation will likely deepen through 2035.

Conclusion

The pharmerging market is being reshaped by biosimilar adoption, enabling cost-effective biologic therapy at population scale. As domestic manufacturing capacity expands and regulatory frameworks mature, biosimilars will likely become the dominant biologic modality in emerging economies.

FAQ

Q1: What settings drive biosimilar adoption in pharmerging markets?
A: Government tenders award volume-based contracts to lowest-cost biosimilar suppliers. National reimbursement lists include biosimilars to expand treatment access. Domestic manufacturers compete on price for public procurement. Oncology and diabetes programs prioritize biosimilar adoption. Comprehensive tender adoption.

Q2: What improvement is enhancing biosimilar market share?
A: Interchangeability designations enable pharmacy-level substitution. Real-world evidence confirms biosimilar safety and efficacy. Domestic manufacturing reduces import costs. Export-oriented production enables technology transfer and scale. Market enhancement.

#PharmergingMarket #Biosimilars #TenderProcurement